完整参考文献（GB/T 7714）
[1] Mavromatis LA, Grams ME. print. Epidemiology of cardiovascular-kidney-metabolic syndrome[J]. Nature Reviews Nephrology, 2026.
[2] Lassen MCH, Ostrominski JW, Claggett BL, et al. Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study[J]. Circulation, 2026, 153(17): 1268-1280.
[3] Alicic RZ, Neumiller JJ, Tuttle KR. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease[J]. Nature Reviews Nephrology, 2026, 22(4): 265-282.
[4] Kuo YJ, Chen LF, Chen Y, et al. Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2026, 27(9): 4120.
[5] Zeitler E, Klein KR, Lingvay I, et al. Online ahead of print. Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome[J]. DIABETES OBESITY and METABOLISM, 2026.
[6] Hsu CN, Tain YL. Melatonin as a Redox Modulator in Developmental Programming: Implications for Cardiovascular-Kidney-Metabolic Risk[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2026, 27(5): 2390.
[7] Zheng Z, Yin X, Liu J, et al. Triglyceride-glucose index and its derivatives as emerging biomarkers of insulin resistance for prognostic evaluation of cardiovascular-kidney-metabolic syndrome: mechanisms and clinical applications[J]. Frontiers in Pharmacology, 2026, 17: 1787130.
[8] Han X, Ding J, Li J, et al. Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular-Kidney-Metabolic Syndrome Stages 2-3[J]. DIABETES OBESITY and METABOLISM, 2026.
[9] Duan Shoupeng, Wang Yijun, Yang Xiaomeng, et al. Explainable machine learning-driven predictive modelling of incident cognitive impairment in individuals with early-stage cardiovascular-kidney-metabolic syndrome: Insights from a longitudinal CHARLS cohort study[J]. Diabetes, obesity & metabolism, 2026, 28(3): 1693-1709.
[10] Ferreira JP, Marques P, Anker SD, et al. Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular-kidney-metabolic conditions: A pooled analysis of randomised trials[J]. DIABETES OBESITY and METABOLISM, 2026, 28(2): 1105-1115.
[11] Hartsell SE, Wei G, Singh R, et al. Online ahead of print. Comparative Effectiveness of SGLT2 Inhibitor and GLP-1 Receptor Agonist on Kidney and Cardiovascular Outcomes by Kidney Failure Risk[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2026.
[12] Palazzuoli A, Mattioli AV, Fedele F. Current Appraisal and Gaps in Knowledge in Cardio-Kidney Metabolic Syndrome Definition[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2026, 27(4): 1657.
[13] Niu G, Cai X, Yang Y, et al. Association of Cardiovascular-Kidney-Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study[J]. Diabetes, obesity & metabolism, 2026, 28(5)(5): 4148-4161.
[14] Li J, Miao X, Li Z, et al. Advancing brain health prevention using explainable CKM-based predictive modelling[J]. Diabetes, obesity & metabolism, 2026, 28(3)(3): 2497-2498.
[15] Singar S, Kachouei AA, Lantigua-Somoano L, et al. Ultra-Processed Foods and the Cardiovascular-Kidney-Metabolic Continuum: Integrating Epidemiological, Multi-Omics, and Translational Evidence[J]. Nutrients, 2026, 18(7): 1039.
[16] Tu J, Chen F, Yan W, et al. 2026. Development and validation of a prediction model for cardiovascular-kidney-metabolic syndrome progression: a multicenter study[J]. Frontiers in Nutrition, 2026, 13: 1783262.
[17] Wen W, Liu Z, Li L, et al. Multimodal mechanisms of di (2-ethylhexyl) phthalate-induced cardiovascular-kidney-metabolic syndrome: Integrating epidemiology, network toxicology and experimental validation[J]. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2026, 309: 119515.
[18] Amujilite, Yin G, Chen Z, et al. Urinary metal mixtures and cardio-kidney-metabolic risk in adults from a legacy-contaminated area: Repeated-measures cohort evidence and computational validation[J]. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2026, 314: 120039.
[19] Soliman GA. Cardiovascular-Kidney-Metabolic (CKM) Syndrome Staging and Relevance to Precision Nutrition[J]. Nutrients, 2026, 18(9): 1430.
[20] Zhu R, Wang R, He J, et al. Associations of cardiovascular-kidney-metabolic syndrome stages with premature mortality and the role of social determinants of health[J]. Journal of Nutrition Health and Aging, 2025, 29(4): 100504.
[21] Claudel SE, Schmidt IM, Waikar SS, et al. Cumulative Incidence of Mortality Associated with Cardiovascular-Kidney-Metabolic (CKM) Syndrome[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36(7): 1343-1351.
[22] Masrouri S, Ebrahimi N, Hasanpour A, et al. Cardiovascular-kidney-metabolic syndrome stages, stage transitions, and risk of cardiovascular disease and mortality: The Tehran Lipid and Glucose Study[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 235: 113223.
[23] Ren H, Hu M, Yan Y, et al. Association of the metabolic dysfunction-associated steatotic liver disease with cardiovascular and kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 229: 112927.
[24] Xie Z, Yu C, Cui Q, et al. Global Burden of the Key Components of Cardiovascular-Kidney-Metabolic Syndrome[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2025, 36(8): 1572-1584.
[25] Trimarco V, Izzo R, Pacella D, et al. Increased prevalence of cardiovascular-kidney-metabolic syndrome during COVID-19: A propensity score-matched study[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 218: 111926.
[26] Baker-Smith CM, Gauen AM, Petito LC, et al. Prevalence of Cardiovascular-Kidney-Metabolic Stages in US Adolescents and Relationship to Social Determinants of Health[J]. Journal of the American Heart Association, 2025, 14(10): e040269.
[27] Liu S, Man Q, Wang S, et al. Kidney function decline mediates the adverse effects of arterial stiffness on all-cause and cardiovascular disease mortality in Cardiovascular-Kidney-Metabolic syndrome population: A cohort study[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 231: 113051.
[28] Yang Y, Liu Y, Han S, et al. Comparative Associations of Traditional and New Obesity Framework With Cardio-Kidney-Metabolic Syndrome and All-Cause Mortality: A Prospective Cohort Study[J]. DIABETES OBESITY and METABOLISM, 2026.
[29] Xie Peichen, Wang Yiqin, Xu Xinghao, et al. Association of Cardiovascular-Kidney-Metabolic Syndrome With Cognitive Decline and Dementia: The ARIC Study Insights[J]. Journal of the American Heart Association, 2025, 14(10): e038445.
[30] Liang J, Liang Y, Chen L, et al. 2025. Cardiovascular-kidney-metabolic progression associated with major adverse liver outcomes: mediating roles of plasma metabolites[J]. Frontiers in Nutrition, 2025, 12: 1675899.
[31] Tian RN, Zhang SX, Zhang N, et al. 2025. Association between the dietary inflammatory index and depressive symptoms in adults with cardiovascular-kidney-metabolic syndrome: evidence of metabolic syndrome as a mediator[J]. Frontiers in Nutrition, 2025, 12: 1623482.
[32] Xiang S, Nie H, Wei Z, et al. Cardiovascular-kidney-metabolic syndrome stages and risk of diverse gastrointestinal diseases: a prospective cohort study and integrative proteomic analysis[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 236: 113266.
[33] Chen H, Wu JY, Yan H, et al. Association of Remnant Cholesterol Inflammatory Index with Stroke, Heart Disease and All-Cause Mortality Across Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: A National Cohort Study[J]. Nutrients, 2026, 18(2): 205.
[34] Xie N, Zeng L, Hu X, et al. Association of remnant cholesterol inflammation index with future cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome stages 0-3[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 233: 113146.
[35] Liu H, Wu S, Huang B, et al. Effect of Mitochondria-Derived Methylmalonic Acid on Progress and Mortality Risk in US Adults With Cardiovascular-Kidney-Metabolic Syndrome[J]. Journal of the American Heart Association, 2026, 15(2): e043066.
[36] Li J, Chen S, Zhang X, et al. The Evolving Role of High-Sensitivity C-Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular-Kidney-Metabolic Syndrome[J]. DIABETES OBESITY and METABOLISM, 2026.
[37] Li Z, Chen M. Serum glycated albumin-to-albumin ratio and mortality risk in cardiovascular-kidney-metabolic syndrome: Evidence from NHANES over 15 years[J]. DIABETES OBESITY and METABOLISM, 2026, 28(3): 2038-2050.
[38] He L, Lin H, Zhang X, et al. Online ahead of print. Risk stratification in early-stage Cardiovascular-Kidney-Metabolic Syndrome: The Potency of visceral adiposity and insulin resistance surrogate indices[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 237: 113336.
[39] Chen Y, Tu H, Liang M, et al. 2025. Association between body roundness index and advanced cardiovascular-kidney-metabolic syndrome[J]. Frontiers in Nutrition, 2025, 12: 1623766.
[40] Lan H, Jia X, Zhao Z, et al. TyG and RC combined with CVD risk in CKM syndrome: A national cohort study[J]. iScience, 2026, 29(3): 115060.
[41] Tang Y, Xu W, Jiang Y, et al. 2026. Associations between lipid-derived indices and cardiovascular-kidney-metabolic syndrome progression among Chinese middle-aged and elderly adults: a longitudinal study[J]. Frontiers in Nutrition, 2026, 13: 1742974.
[42] Yang J, Deng Z, Xie B, et al. 2026. The Triglyceride-Glucose-Chinese Visceral Adiposity Index (TyG-CVAI) outperforms other insulin resistance indices in its association with cardiovascular-kidney-metabolic syndrome severity in type 2 diabetes: a comparative study[J]. Frontiers in Nutrition, 2026, 13: 1817071.
[43] Wang M, Lin W, Liu H, et al. Associations between insulin resistance indices and cardiovascular disease in older adults with cardiovascular-kidney-metabolic syndrome stage 0-3: The GOLD-Health cohort[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 226: 112327.
[44] Zhang C, Chen Y, Wang T, et al. Inflammation and abnormal glucose-lipid metabolism are critical for population stratification toward progressive frailty in Cardiovascular-Kidney-Metabolic syndrome[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 230: 112989.
[45] Agboola OJ, Chan JSK, Spitz JA, et al. The role of inflammation in longitudinal renal function decline and incident chronic kidney disease: the multi-ethnic study of atherosclerosis[J]. European Journal of Preventive Cardiology, 2026, 33(5): 718-728.
[46] Pengfei C, Lui M, Zhang L, et al. 2025. Association of SII and SIRI with incidence of cardiovascular disease in cardiovascular-kidney-metabolic syndrome: a prospective cohort study[J]. Frontiers in Nutrition, 2025, 12: 1661826.
[47] Xu Y. 2025. Association of neutrophil/high-density lipoprotein cholesterol ratio with the cardiovascular-kidney-metabolic syndrome and its cardiovascular mortality[J]. Frontiers in Nutrition, 2025, 12: 1594041.
[48] Duan Y, Yang K, Zhang T, et al. 2025. Association between non-highdensity lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and cardiovascular-kidney-metabolic syndrome: evidence from NHANES 2001-2018[J]. Frontiers in Nutrition, 2025, 12: 1548851.
[49] Huang J, Liu Z, Feng W, et al. 2025. Machine learning with decision curve analysis evaluates nutritional metabolic biomarkers for cardiovascular-kidney-metabolic risk: an NHANES analysis[J]. Frontiers in Nutrition, 2025, 12: 1597864.
[50] Yu H, Liu Y, Zhang T, et al. 2025. Association between dietary inflammatory index score and cardiovascular-kidney-metabolic syndrome: a cross-sectional study based on NHANES[J]. Frontiers in Nutrition, 2025, 12: 1557491.
[51] Shi L, Zhang D, Zhang S. 2025. Association between oxidative balance score with cardiovascular - kidney - metabolic syndrome and all-cause mortality among US population[J]. Frontiers in Nutrition, 2025, 12: 1564368.
[52] Xie D, You F, Yang L, et al. 2025. The role of oxidative balance score in Cardiovascular-Kidney-Metabolic syndrome progression and mortality: insights from NHANES 1999-2020[J]. Frontiers in Nutrition, 2025, 12: 1597693.
[53] Wang Z, Fang L, Wang L, et al. 2025. Non-linear associations and threshold effects of oxidative balance score and composite dietary antioxidant index on frailty risk in patients with cardiovascular-kidney-metabolic syndrome[J]. Frontiers in Nutrition, 2025, 12: 1673736.
[54] He Q, Hu F, Wei W, et al. 2025. Association between the composite dietary antioxidant index and cardiovascular-kidney-metabolic syndrome among U.S. adults: evidence from NHANES 2007-2018[J]. Frontiers in Nutrition, 2025, 12: 1600651.
[55] Li Y, Luo Z, Zhang Z, et al. Exploring the mediating role of TyG-related indicators in the relationship between biological aging and late-stage cardiovascular-kidney-metabolic in middle-aged and older adults[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 230: 112988.
[56] Liu J, Song Y, Luo R, et al. 2025. Association between urinary heavy metals and cardiovascular-kidney-metabolic syndrome: mediating roles of TyG, WWI, and eGFR[J]. Frontiers in Nutrition, 2025, 12: 1613721.
[57] Fan S, Hu H, Li Y, et al. Effects of ambient air pollution mixtures and household fuel use on progression to advanced cardiovascular-kidney-metabolic syndrome among middle-aged and older adults[J]. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2025, 303: 118915.
[58] Fu P, Zheng H, Wu K, et al. 2026. Adherence to the EAT-Lancet diet and the risk of heart failure in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: A prospective cohort study[J]. Frontiers in Nutrition, 2026, 13: 1802388.
[59] Tang H, Zhang X, Luo N, et al. Temporal trends in the planetary health diet index and its association with cardiovascular, kidney, and metabolic diseases: A comprehensive analysis from global and individual perspectives[J]. Journal of Nutrition Health and Aging, 2025, 29(5): 100520.
[60] Zhang LL, Zhu XG, Chen J, et al. Association of Higher Dietary Omega-3 Fatty Acid Intake With Cardiovascular-Kidney-Metabolic Syndrome Stage Severity and Mortality in US Adults: A Cross-Sectional and Prospective Cohort Analysis of NHANES 1999 to 2018[J]. Journal of the American Heart Association, 2026, 15(2): e046079.
[61] Long D, Mao C, An H, et al. 2025. Association between dietary index for gut microbiota and cardiovascular-kidney-metabolic syndrome: a population-based study[J]. Frontiers in Nutrition, 2025, 12: 1594481.
[62] Tu D, Sun J, Wang P, et al. Overall Sleep Quality Is Associated With Advanced Stages in Patients With Cardiovascular-Kidney-Metabolic Syndrome[J]. Journal of the American Heart Association, 2025, 14(7): e038674.
[63] Drexler Y, Fornoni A. Advances in risk prediction and treatment strategies for CKM syndrome[J]. Nature Reviews Nephrology, 2026, 22(2): 95-96.
[64] Ma J, Li P, Tao L, et al. Environment-wide association study of cardiovascular-kidney-metabolic syndrome based on NHANES 2013-2016[J]. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2025, 303: 118993.
[65] Yang Y, Zhou W, Yang M, et al. Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome[J]. Frontiers in Pharmacology, 2026, 17: 1800868.
[66] Ao N, Du J, Jin S, et al. The cellular and molecular mechanisms mediating the protective effects of sodium-glucose linked transporter 2 inhibitors against metabolic dysfunction-associated fatty liver disease[J]. DIABETES OBESITY and METABOLISM, 2025, 27(2): 457-467.
[67] Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity[J]. Clinical Kidney Journal, 2024, 17(Suppl.
[68] Moreno-Pérez O, Reyes-García R, Modrego-Pardo I, 等. 2024 Apr. Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?[J]. Clinical Kidney Journal, 2024, 17(4): sfae039.
[69] Hao WR, Liu JC, Fang YA, et al. Cardiorenal protective effects of anti-diabetic drugs in early stage Cardiovascular-Kidney-Metabolic Syndrome: A multicenter, time-varying analysis[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 236: 113233.
[70] Levin A, Bansal N, de Boer IH, et al. Online ahead of print. The Kidney in the Middle: KDIGO Guidelines Address Multiple Key Components of Cardiovascular-Kidney-Metabolic Syndrome[J]. KIDNEY INTERNATIONAL, 2026.
[71] Ortiz A, Arreola Guerra JM, Chan JCN, et al. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. KIDNEY INTERNATIONAL, 2025, 108(4): 555-571.
[72] Bollinger E, Williams G, Piper ME, et al. Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models[J]. KIDNEY INTERNATIONAL, 2025, 108(2): 310-316.
[73] Ren X, Gao D, Yun R, et al. A urea-activated nanocarrier for site-specific SGLT2 inhibition and metabolic rescue against cardiovascular-kidney-metabolic syndrome[J]. Nature Communications, 2026.
[74] Bi X, Shen Y, Shen Y, et al. 2025 Apr. Prognosis of non-albuminuric patients with the cardiovascular-kidney-metabolic syndrome[J]. Clinical Kidney Journal, 2025, 18(4): sfaf074.
[75] Caramori ML, Repetto E, Perkins C, et al. Cardio-Kidney-Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease[J]. DIABETES OBESITY and METABOLISM, 2026, 28(5): 4344-4351.
[76] Lawton E, Perz L, Pasqua MR, et al. Online ahead of print. Continuous Ketone Monitoring Captures Overt Ketosis in Type 1 Diabetes Caused by Empagliflozin, Low-Carbohydrate Diet, and Exercise[J]. Diabetes Technology and Therapeutics, 2026.
[77] Kong YW, Morrison D, Lu JC, et al. Continuous ketone monitoring: Exciting implications for clinical practice[J]. DIABETES OBESITY and METABOLISM, 2024, 26.
[78] Marchetti M, Antiochos P, Pitta-Gros B, et al. Prognostic Impact of Cardiovascular-Kidney-Metabolic Overlap Among Patients With Acute Heart Failure: Insights From a Real-World Multinational Cohort[J]. Journal of the American Heart Association, 2026, 15(1): e045294.
[79] Li J, Lei L, Zhang L, et al. Cardiovascular-kidney-metabolic overlaps, clinical outcomes, and quality of life in patients with acute heart failure[J]. Journal of Nutrition Health and Aging, 2025, 29(8): 100613.
[80] Wang L, Zhang X, Chen Y, et al. Reduced Risk of Cardiovascular Diseases After Bariatric Surgery Based on the New Predicting Risk of Cardiovascular Disease EVENTs Equations[J]. Journal of the American Heart Association, 2025, 14(6): e038191.
[81] Clark WR, Mueller BA, Kraus MA, et al. Quantification of creatinine kinetic parameters in patients with acute renal failure[J]. KIDNEY INTERNATIONAL, 1998, 54(2): 554-60.
[82] Canaud B, Leblanc M, Garred LJ, et al. Protein catabolic rate over lean body mass ratio: a more rational approach to normalize the protein catabolic rate in dialysis patients[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 30(5): 672-9.
[83] Li J, Lei L, Wang W, et al. Social Risk Profile and Cardiovascular-Kidney-Metabolic Syndrome in US Adults[J]. Journal of the American Heart Association, 2024, 13(16): e034996.
[84] Ding X, Tian J, Chang X, et al. Association between remnant cholesterol and the risk of cardiovascular-kidney-metabolic syndrome progression: insights from the China health and retirement longitudinal study[J]. European Journal of Preventive Cardiology, 2025, 32(13): 1157-1165.
[85] Abudoureheman W, Zhang F, Sun Q. ahead of print. Remnant Cholesterol in CHARLS: Unaddressed Dynamic Changes and Clinical Confounders in CKM Progression Analysis[J]. European Journal of Preventive Cardiology, 2025.
[86] Liu Z, Zhou D, Tang Y, et al. Association of Atherogenic Index of Plasma With Stroke Risk in a Population With Cardiovascular-Kidney-Metabolic Syndrome Stages 0 to 3: The First Evidence From the China Health and Retirement Longitudinal Study[J]. Journal of the American Heart Association, 2025, 14(14): e039983.
[87] Ha KH, Kim DJ, Lee H. ahead of print. MASLD in the CKM health framework: what does it add to the table?[J]. European Journal of Preventive Cardiology, 2025.
[88] Gao Q, Ren W, Du X, et al. ahead of print. Sex-Specific Associations Between Depression and Cardiovascular-Kidney-Metabolic Syndrome Progression: A National Cohort Study[J]. European Journal of Preventive Cardiology, 2026.
[89] Shi P, Lou C, Fang J, et al. Adverse Life Events Across the Life Course and the Risk of New-Onset Cardiovascular-Kidney-Metabolic Multimorbidity in Middle-Aged and Older Adults: Longitudinal Evidence From CHARLS[J]. Journal of the American Heart Association, 2025, 14(24): e045192.
[90] Fang Y, Huang S, Zhang H, et al. ahead of print. Frailty as a Risk-Enhancing Factor Across the Cardiovascular-Kidney-Metabolic Framework: Findings from the UK Biobank[J]. European Journal of Preventive Cardiology, 2026.
[91] Wang A, Li Y. Finerenone in CKD from Estimands to Clinical Interpretability under Competing Risk[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2026, 37(2): 425-426.
[92] Zhang X, Zhu X, Gu W, et al. Elucidating the mechanism of phthalates induced osteoporosis through network toxicology and molecular docking[J]. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2025, 291: 117820.
[93] Luo J, Guo M, Xie K, et al. Metabolomic analysis of Agkistrodon haly venom poisoning mouse treatment by Jidesheng snake pill based on GC-MS[J]. Frontiers in Pharmacology, 2024, 15: 1419609.
[94] Sun J, Liu PF, Liu JN, et al. Combined metabolomics and proteomics to reveal beneficial mechanisms of Dendrobium fimbriatum against gastric mucosal injury[J]. Frontiers in Pharmacology, 2022, 13: 948987.
[95] Varillas-Delgado D. Influence of Genetic Polymorphisms and Biochemical Biomarkers on Response to Nutritional Iron Supplementation and Performance in a Professional Football Team: A Pilot Longitudinal Study[J]. Nutrients, 2025, 17(8): 1379.
[96] Kristjansson RP, Oddsson A, Helgason H, et al. Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase[J]. Nature Communications, 2016, 7: 10572.
[97] Tain YL, Hsu CN. Amino Acids during Pregnancy and Offspring Cardiovascular-Kidney-Metabolic Health[J]. Nutrients, 2024, 16(9): 1263.
[98] Lizcano-Álvarez Á, Varillas-Delgado D, Cano-de-la-Cuerda R. The Association of Genetic Markers Involved in Muscle Performance Responding to Lactate Levels during Physical Exercise Therapy by Nordic Walking in Patients with Long COVID Syndrome: A Nonrandomized Controlled Pilot Study[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25(15): 8305.
[99] Varillas-Delgado D. Association of Genetic Profile with Muscle Mass Gain and Muscle Injury Prevention in Professional Football Players after Creatine Supplementation[J]. Nutrients, 2024, 16(15): 2511.
[100] Peng Y, Yan L, Zhao C, et al. Effects of Temperature and Salinity on Ovarian Development and Differences in Energy Metabolism Between Reproduction and Growth During Ovarian Development in the Lateolabrax maculatus[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26(17): 8295.
[101] Mathew GG. Finerenone in CKD: Enhancing the Evidence Base in Real-World Contexts[J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2026, 37(2): 423-424.
[102] Yin S, Yan S, Yang Z, et al. Association between Life's Simple 7 and life's essential 8 with all-cause and cardiovascular mortality in cardiovascular-kidney-metabolic syndrome population[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2026, 231: 113064.
[103] Haas NL, Korley FK, Schneider RM, et al. Online ahead of print. Continuous Ketone Monitoring in Diabetic Ketoacidosis: Prospective Multicenter Method-Comparison and Feasibility Study[J]. Diabetes Technology and Therapeutics, 2026.
[104] Yang Z, Zhou P, Fan F, et al. A simple score, CKM(2)S(2)-BAG, to predict cardiovascular risk with cardiovascular-kidney-metabolic health metrics[J]. iScience, 2025, 28(7): 112780.
[105] Yang M, Su C, Chang X, et al. ahead of print. Data-driven cluster analysis identifies distinct types of cardiovascular-kidney-metabolic syndrome[J]. European Journal of Preventive Cardiology, 2025.